Smith Kline & French

Smith Kline & French, commonly written as Smith, Kline & French and abbreviated SKF, was an American pharmaceutical company based in Philadelphia. Its history began with John K. Smith's drugstore business, established in 1875, and the company developed from a regional pharmaceutical concern into an international prescription-drug manufacturer. The business is important primarily as a predecessor of GlaxoSmithKline rather than as a currently operating standalone brand. The company expanded through the development, licensing, and commercialization of prescription medicines. Among the products associated with its history were Thorazine, the brand name used for chlorpromazine, and Tagamet, the brand name for cimetidine. Thorazine became a major treatment in psychiatry and helped establish SKF's profile in central-nervous-system medicines. Tagamet, introduced in the 1970s, was an important H2-receptor antagonist for acid-related disorders and became one of the best-known prescription medicines of its era. The company also marketed other medicines and consumer-oriented products at different points in its history, but its strongest historical identity was as a research-based prescription pharmaceutical company. SKF's corporate identity changed as the pharmaceutical industry consolidated. In 1989, Beecham Group acquired SmithKline Beckman, the company that had emerged from earlier Smith Kline & French combinations and related transactions. The acquisition created SmithKline Beecham, a major international healthcare company. In 2000, SmithKline Beecham merged with Glaxo Wellcome to form GlaxoSmithKline, now known as GSK. As a result, Smith Kline & French ceased to exist as an independent operating company, while selected products, scientific assets, trademarks, and historical businesses continued within successor organizations. The name should not be confused with a current generic-drug manufacturer. SKF was principally associated with branded prescription pharmaceuticals and pharmaceutical research. Its historical significance lies in the transition from a nineteenth-century American drug business to a multinational pharmaceutical enterprise and in the contribution of its medicines and corporate assets to the lineage of present-day GSK.

Smith Kline & French originated in Philadelphia in the nineteenth century. John K. Smith established the business in 1875, initially as a drugstore and pharmaceutical enterprise. Mahlon Kline joined the business during its early development, and the company subsequently adopted the Smith, Kline & Company name. The business later incorporated the French name through corporate succession and expansion, becoming Smith, Kline & French. During the twentieth century, SKF moved beyond local distribution and pharmacy operations toward the development and marketing of prescription medicines. This shift reflected the growing importance of scientific research, physician-directed prescribing, clinical evidence, and organized pharmaceutical sales. The company became especially associated with medicines affecting the central nervous system and gastrointestinal tract. Its best-known historical products included Thorazine, the SKF-associated brand for chlorpromazine, and Tagamet, the brand name for cimetidine. Thorazine became an influential psychiatric medicine after chlorpromazine entered clinical use in the 1950s. Its adoption helped transform the treatment of serious mental illness and made SKF a prominent pharmaceutical company. Tagamet represented another major stage in the company's history. Cimetidine was an H2-receptor antagonist used for acid-related gastrointestinal conditions and became a commercially important prescription medicine after its introduction in the 1970s. The product's success demonstrated the value of pharmaceutical research targeted at common, clinically significant conditions. SKF participated in the broader consolidation of the pharmaceutical sector. It became part of SmithKline Beckman through earlier corporate combinations, and in 1989 Beecham Group acquired SmithKline Beckman. The resulting organization was named SmithKline Beecham and operated as a major international healthcare company. This transaction ended Smith Kline & French's existence as an independent corporate entity, although its product history and scientific legacy continued through the successor company. In 2000, SmithKline Beecham merged with Glaxo Wellcome to create GlaxoSmithKline, later styled GSK. The transaction brought the Smith Kline & French lineage into one of the world's largest pharmaceutical groups. The SKF name is therefore principally historical: it identifies an important predecessor company rather than a current standalone pharmaceutical manufacturer. Its legacy survives through successor-company archives, product histories, trademarks, and medicines developed or commercialized during the SKF and SmithKline Beecham periods.

1. 2000The business became part of GlaxoSmithKline

   SmithKline Beecham merged with Glaxo Wellcome, creating GlaxoSmithKline and ending the standalone corporate lineage.

   Source
2. 1989Beecham acquired SmithKline Beckman

   Beecham's acquisition brought the Smith Kline & French successor business into SmithKline Beecham.

   Source
3. 1977Tagamet was introduced

   SKF introduced Tagamet, the brand name for cimetidine, an H2-receptor antagonist used for acid-related gastrointestinal conditions.

   Source
4. 1950Thorazine became associated with SKF

   SKF marketed Thorazine, the brand name for chlorpromazine, which became an influential medicine in psychiatric treatment.

   Source
5. 1875John K. Smith established the business

   John K. Smith founded the Philadelphia drug business that developed into Smith, Kline & French.

   Source

Historical American research-based pharmaceutical company, particularly associated with branded prescription medicines and pharmaceutical innovation.

• ThorazinePrescription medicine1950

  Thorazine was the SKF-associated brand name for chlorpromazine, a phenothiazine antipsychotic. It became one of the historically important medicines in modern psychiatric treatment and was also used for other indications, including severe nausea and agitation. Its adoption helped establish SKF's reputation as a company active in central-nervous-system pharmaceuticals.

• TagametPrescription gastrointestinal medicine1977

  Tagamet was the brand name for cimetidine, an H2-receptor antagonist that reduces gastric acid secretion. It was used in the treatment of peptic-ulcer disease and related acid disorders. Its commercial and clinical importance made it one of the signature products associated with the Smith Kline & French lineage.

• 2000Formation of GlaxoSmithKlineM&A

  SmithKline Beecham and Glaxo Wellcome were both major international pharmaceutical groups seeking greater scale and a broader product portfolio.

  What changed. The two companies merged to form GlaxoSmithKline.

  Aftermath. The Smith Kline & French lineage became part of GSK, where it remained relevant as a historical and product-development predecessor rather than a standalone brand.

  Source
• 1989Beecham acquisition of SmithKline BeckmanM&A

  The pharmaceutical industry was undergoing international consolidation, and SmithKline Beckman represented the successor organization carrying the Smith Kline & French corporate heritage.

  What changed. Beecham Group acquired SmithKline Beckman and combined the businesses under the SmithKline Beecham name.

  Aftermath. Smith Kline & French ceased to operate as an independent company, while its products, research assets, and organizational history continued within SmithKline Beecham.

  Source

• 2000SmithKline Beecham and Glaxo Wellcome merged

  The merger of SmithKline Beecham and Glaxo Wellcome created GlaxoSmithKline, ending the independent corporate history of the Smith Kline & French successor businesses.

  M&A
  Source
• 1989Beecham acquired SmithKline Beckman

  Beecham Group acquired SmithKline Beckman, bringing the Smith Kline & French corporate lineage into the business that became SmithKline Beecham.

  M&A
  Source

1. GSK history
2. Chlorpromazine
3. Cimetidine